secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0000950170-25-092528
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd forms SPEAR Study Group with top researchers to test mAbs for Long COVID
--------------------------------------------------------------------------------

- SPEAR Study Group includes Drs. Michael Peluso, Amy Proal, David Putrino; will evaluate PEMGARDA and VYD2311.
- Up to 5% of Americans report Long COVID symptoms; no approved treatments exist for the condition.
- PEMGARDA currently authorized only for COVID-19 prophylaxis; not approved for Long COVID treatment.
- Invivyd plans FDA meeting early 3Q 2025 to discuss rapid approval pathways for COVID-19 mAbs.
- Anecdotal reports suggest pemivibart may relieve Long COVID symptoms; rigorous clinical trials are planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025092528/0000950170-25-092528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025092528/ivvd-20250702.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-092528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer